JAJoan Oluwadamilola Ajayi

Joan Oluwadamilola Ajayi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joan Oluwadamilola Ajayi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of kidney dysfunction on blood-brain barrier integrity and neurological conditions

    by Nicholas Aderinto, Gbolahan Olatunji, Emmanuel Kokori, Ikponmwosa Ogieuhi, Komolafe Babajide Ayodeji, Victor Oluwatomiwa Ajekiigbe, Muhammadul-Awwal Irodatullah Bisola, Joan Oluwadamilola Ajayi, Chinonyelum Agbo, Oluwatobi Omoworare, et al.

    The kidney–brain axis represents a bidirectional pathophysiological link between chronic kidney disease (CKD), acute kidney injury (AKI), and blood–brain barrier (BBB) dysfunction. CKD affects over 800 million individuals globally and is associated with accelerated cognitive decline, stroke, and neurodegenerative disorders. This review synthesizes evidence that uremic toxins, systemic inflammation, oxidative stress, hormonal dysregulation (erythropoietin deficiency, RAAS activation), and gut dysbiosis converge to impair BBB integrity via tight junction degradation, endothelial activation, and pericyte–astrocyte decoupling. These alterations facilitate neuroinflammation, neurotoxicity, and leukocyte infiltration, contributing to the pathogenesis of stroke, Alzheimer’s disease, Parkinson’s disease, epilepsy, and CKD-associated leukoencephalopathy. Hemodialysis-induced osmotic shifts and sleep fragmentation further exacerbate BBB and glymphatic dysfunction. Preserving BBB integrity through uremic toxin reduction, anti-inflammatory strategies, RAAS inhibition, and lifestyle interventions (e.g., exercise) emerges as a critical therapeutic goal. Future research must prioritize biomarker validation (claudin-5, S100B), neuroimaging correlations, and targeted BBB-protective therapies to mitigate neurological morbidity in renal disease.


  • Open Access

    Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence

    by Gbolahan Olatunji, Nicholas Aderinto, Emmanuel Kokori, Michael Awoyinfa, Oluwafemi Ajimotokan, Joan Oluwadamilola Ajayi, Nitin Narayan Rao, Ajayi Oluwatomisin Temidayo, Tejiri Napoleon, Chimezirim Ezeano, et al.

    Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.